Shree Ganesh Remedies Ltd

Shree Ganesh Remedies Limited reported its unaudited financial results for Q1FY27, showing a significant year-on-year decline. Revenue from operations stood at ₹14.36 crore, down 42% YoY. EBITDA decreased by 54% YoY to ₹3.35 crore, and Profit After Tax (PAT) fell by 68% YoY to ₹1.12 crore. The company cited subdued European demand, geopolitical uncertainty, raw material volatility, and the automatic termination of an agreement with an EU distributor as key reasons for the challenging quarter. Management expects a transition period of a couple of quarters before volumes recover, with a return to prior run-rate levels anticipated in H2FY27. Engagements in South-East Asia for CRAMS are progressing, expected to contribute from H2FY27. The company has moderated its FY27 guidance due to these headwinds.

Shree Ganesh Remedies Ltd announced the appointment of M/s. M. I. Prajapati & Associates LLP as Cost Auditors for the financial year 2026-2027. This decision was made by the Board of Directors, based on the recommendation of the Audit Committee. The board also approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026, and appointed Mr. Vishal Thawani as Scrutinizer for the upcoming 31st Annual General Meeting. The company also provided notice for the AGM and the Directors' Report for the year ended March 31, 2026.

Shree Ganesh Remedies Ltd announced the outcome of its Board Meeting held on August 12, 2026. The board approved the Unaudited Standalone & Consolidated Financial Results for the quarter ended June 30, 2026. Additionally, the company appointed M/s. M. I. Prajapati & Associates LLP as Cost Auditors for the year 2026-2027 and Mr. Vishal Thawani as Scrutinizer for the upcoming 31st Annual General Meeting. The notice for the AGM and the Directors' Report for the year ended March 31, 2026, were also approved.

Shree Ganesh Remedies' consolidated PAT for Q1 FY27 fell 67.5% YoY to ₹1.12 Cr (₹3.45 Cr in Q1 FY26) as revenue from operations dropped 41.8% YoY to ₹14.36 Cr (₹24.67 Cr). Sequentially the decline is sharper still — revenue down 56.7% and PAT down 82.1% versus the seasonally strong Q4 FY26 (₹33.20 Cr revenue, ₹6.27 Cr PAT). Standalone and consolidated numbers are identical this quarter since the wholly-owned US subsidiary, SGRL USA Inc, again contributed NIL revenue and is immaterial to the group, per the auditor's review report. No analyst consensus or brokerage preview for this quarter could be located — the stock is thinly covered — so vsStreet is unknown rather than inferred. Margins compressed on both counts: net profit margin (PAT/total income) fell to 7.3% from 13.6% YoY and 18.3% QoQ, while operating margin fell to 23.3% from 29.6% YoY and 34.3% QoQ. The compression sits mainly on operating deleverage — cost of materials (₹8.40 Cr) and employee costs (₹2.93 Cr) held roughly flat even as revenue nearly halved sequentially — partly offset by a ₹6.31 Cr finished-goods/WIP inventory build (versus a ₹0.13 Cr build a year ago), which kept reported expenses from falling as much as the topline. Finance costs eased to ₹0.32 Cr from ₹0.94 Cr YoY and ₹0.88 Cr QoQ, providing a small cushion to pre-tax profit. Against management's own May 2026 guidance — a 'gradual improvement in momentum through FY27' driven by the new Block-7 capacity (guided to start production in Q2 FY27, i.e. after this quarter) and CRAMS business traction building 'later in the year' — the Q1 print runs counter to that narrative rather than confirming it: both revenue and profit fell sharply before the capacity addition has even come online, extending the 'consolidation year' softness flagged for FY26 rather than showing the promised inflection. No management press release commentary was available in the record to corroborate or contextualise the numbers. Corporate actions this quarter (a new independent director appointment on Jul 17, an insider-trading window closure on Jun 25, a share-price-movement clarification on Jun 29) are administrative and do not explain the operating decline.

Shree Ganesh Remedies Ltd has announced that its Board of Directors will convene on August 12, 2026. The primary agenda item is to consider and approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. Additionally, the company has closed its trading window from July 1, 2026, and it will remain shut for 48 hours post-announcement of the financial results, in compliance with insider trading regulations.

Shree Ganesh Remedies Ltd announced the appointment of Ms. Hiral Ankitkumar Shah as an Additional Director, designated as Non-Executive Independent Director. This appointment is effective from July 17, 2026, for a term of five years, subject to shareholder approval. Ms. Shah is a qualified Company Secretary with over 14 years of experience in corporate governance, legal, secretarial, and regulatory compliance. She has confirmed she is not debarred from holding a director position by any regulatory authority.

Shree Ganesh Remedies Ltd has responded to a clarification request from BSE regarding significant movement in its share price. The company stated that the price fluctuation is purely market-driven and not influenced by any specific management knowledge or control. The management affirmed their commitment to making all relevant disclosures as per SEBI regulations.

Shree Ganesh Remedies Ltd has announced the closure of its trading window for dealing in the company's securities. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut for all 'Designated Persons' and their 'Immediate Relatives' starting from Wednesday, July 01, 2026. It will reopen 48 hours after the announcement of the company's Unaudited Financial Results for the quarter ending June 30, 2026. The exact date for the Board Meeting to consider these financial results will be communicated later.

Shree Ganesh Remedies Ltd reported its Q4 and FY26 financial results. For the year ended March 31, 2026, the company's revenue stood at ₹109.29 Cr, a 1% increase YoY, while EBITDA decreased by 11% to ₹35.02 Cr, and PAT decreased by 23% to ₹17.77 Cr. The company is progressing on CRAMS engagements and expects commercial production from Block 7 expansion to commence in Q2FY27. The management noted FY26 as a year of consolidation, with a focus on strengthening the business foundation.

Shree Ganesh Remedies Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board also approved the re-appointment of M/s. S N D K & Associates LLP as Internal Auditors for FY 2026-27. The auditors issued unmodified opinions on the financial results.